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Treatment with Enzalutamide (ENZ) prolongs survival
in patients with incurable castration-resistant prostate
cancer (CRPC). However, the rapid recurrence of ENZ
resistant tumors and the increased incidence of lethal
neuroendocrine cancers in CRPC patients underscore
the need for understanding how aggressive cell types
emerge in resistant disease in order to design more
effective therapies. As an unbiased approach to uncover-
ing novel mechanisms of ENZ resistance, ENZ resistant
cells were established from castration-resistant LNCaP
xenografts that recurred under ENZ treatment in vivo
and were genetically profiled using Illumina Platform
gene expression analysis as well as RNA Seq. Genes
involved in myeloid cell differentiation and immune
checkpoint responses, as well as neuroendocrine differ-
entiation, were strongly upregulated in ENZ resistant
cell lines compared to CRPC controls. To investigate
whether ENZ resistant cells may pass through a “dedif-
ferentiated” state allowing progression to a neuroendo-
crine phenotype with immune-evasive properties,
markers of cancer stem cells (CD133, CD44, CD117,
CD49F, TROP2) neuroendocrine cells (neuron specific
enolase, snaptophysin, chromagranin A, aurora kinase
A, NCAM-1) and immune-evasion (programmed death
ligands-1 and 2, B7H3, ICOSL) were assessed by quanti-
tative PCR and flow cytometry. Indeed, all cancer stem
cell markers were expressed at a higher frequency on
ENZ resistant cells than CRPC controls and neuroendo-
crine markers were highly upregulated. Consistent with
gene profiling results suggestive of a myeloid differentia-
tion process, neuroendocrine-like resistant cells dis-
played an “immune” phenotype, expressing cell surface
markers and transcription factors characteristic of den-
dritic cells (CD11c, HLA-DR, IRF8, ID2, AHR, BATF)
that were absent from CRPC cells. Moreover, a greater
frequency of neuroendocrine-like ENZ resistant cells
expressed PD-L1, PD-L2 and ICOSL, and they showed
intense staining for B7H3. Each of these molecules is
well known to limit T cell effector responses and have
been implicated in immune evasion strategies of solid
tumors. Taken together, our results suggest that acquisi-
tion of resistance to Enzalutamide promotes the emer-
gence of neuroendocrine-like cells that may be able to
subvert anti-tumor T cell responses via dysregulation of
antigen presentation or by enhancing immune check-
point signaling. These results support anecdotal findings
of increased frequency of neuroendocrine prostate can-
cer in patients undergoing long-term androgen withdra-
wal therapy and suggest investigating the utility of
immunotherapies, such as anti-CTLA-4 or PD-1, in this
subset of patients.
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